- Link:
- http://hdl.handle.net/1721.1/35555
- Collection:
-
- Subjects
- Harvard University--MIT Division of Health Sciences and Technology. Sloan School of Management. Harvard University--MIT Division of Health Sciences and
Technology.
- Creator:
- Subramaniam, Sundar
- Contributors:
- Sloan School of Management. Harvard University--MIT Division of Health Sciences and Technology. Frank Douglas.
- Format
- 48 leaves
- Format
- 2474316 bytes
- Format
- 2474664 bytes
- Format
- application/pdf
- Language
- eng
- Publisher
- Massachusetts Institute of Technology
- Rights
- M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See
provided URL for inquiries about permission.
- Rights
- http://dspace.mit.edu/handle/1721.1/7582
- Type
- Thesis
- Description
- For a growing number of indications, combination
therapies are becoming increasingly common due in part to their
superior efficacy, as compared to monotherapies. In fact, in the
case of infectious diseases such as AIDS and tuberculosis,
combination therapies are now the standard of care. With the
emergence of drug-device combinations, genetic testing, and
individualized medicine, this trend towards combination therapies
is likely to continue to grow. In this context the pricing of
combination therapies is a critical component that needs to be
understood by medical practitioners, payors and policy makers.
There are three factors to consider in the pricing of combination
therapies: the characteristics and structure of the market in which
the combined product is sold, the absence or presence of market
exclusivity, and the prices of the components of the combined
product, when sold individually. When one or more of the components
of the combined product has market exclusivity, additional factors
such as exclusionary bundling, tying, and double marginalization
may come into play.
- Description
- (cont.) In this thesis I discuss combination
therapies, describe the factors that can affect the pricing of
combination therapies, and then attempt to identify the
relationships among component pricing, market forces, market
exclusivity and the pricing of combination therapies. To illustrate
these relationships empirically, I will analyze data from a sample
of unified combined drugs, a subset of combination therapies. The
results of this analysis are consistent with a hypothesis that, for
combination drugs with a patented ingredient, the elimination of
double marginalization by efficient transfer pricing and economic
and exclusionary bundling, lowers the price of the unified
combination drug relative to the price of its
constituents.
- Description
- b y Sundar Subramaniam.
- Description
- Thesis (S.M.)--Harvard-MIT Division of Health
Sciences and Technology; and, (M.B.A.)--Massachusetts Institute of
Technology, Sloan School of Management, 2006.
- Description
- Includes bibliographical references (leaves
47-48).
- Rights
- M.I.T. theses are protected by copyright. They may be
viewed from this source for any purpose, but reproduction or
distribution in any format is prohibited without written
permission. See provided URL for inquiries about
permission.
- Visits:
- 1
- Access:
- Instructions in case access is denied
Site powered by:
